PCSK9 and atherosclerosis: Management of elevated LDL-C, a causal risk factor in the development of atherosclerotic cardiovascular disease (ASCVD), has been revolutionized by using inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9).